In 2003, HE4 was designated as a serum marker for ovarian cancer and was approved by the U.S. Food and Drug Administration in 2009 for monitoring the recurrence and progression of epithelial ovarian cancer [5]. Here, WFDC2 is linked to ovarian cancer.